6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid
• 化学式: C₁₈H₁₄N₄O₅S
• 分子量: 398.4
• InChiKey: OQANPHBRHBJGNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  柳氮磺吡啶 、 6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid 生成 (3Z)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid
  参考文献：
  名称：

  DRUG DEPOTS FOR TREATMENT OF PAIN AND INFLAMMATION IN SINUS AND NASAL CAVITIES OR CARDIAC TISSUE

  摘要：

  提供有效的疼痛和/或炎症治疗。通过在心脏组织附近或鼻腔或鼻窦内植入可生物降解的药物沉积膜、贴片、条或海绵，可以减轻、预防或治疗疼痛和/或炎症。

  公开号：

  US20100239632A1

文献信息

• HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS
  申请人：Yu Chongxi

  公开号：US20100040548A1

  公开（公告）日：2010-02-18

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  该发明提供了一种新型高渗透性复合物（HPC）或高渗透性前药（HPP）的组合物，包括抗微生物和抗微生物相关化合物，这些化合物能够以高渗透效率穿越生物屏障。HPP能够在穿越生物屏障后转化为母药活性药物或药物代谢物，从而可以治疗母药或代谢物所能治疗的疾病。此外，HPP能够到达母药可能无法进入或在目标区域获得足够浓度的区域，从而提供新的治疗方法。HPP可以通过各种给药途径向受试者施用，例如，局部给药到病情作用部位以高浓度，或者系统给药到生物体内并以更快速度进入全身循环。
• ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHODS FOR REDUCING, PREVENTING OR TREATING PAIN AND INFLAMMATION
  申请人：ZANELLA John

  公开号：US20090263489A1

  公开（公告）日：2009-10-22

  Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

  提供了治疗急性疼痛和/或炎症的有效方法，可以持续一段时间。通过在目标部位或附近给予足够的磺胺嘧啶，可以缓解由不同来源引起的疼痛，包括但不限于脊椎盘突出（即坐骨神经痛）、脊柱侧弯、狭窄、盘源性背痛和关节疼痛以及手术后的疼痛。当在可生物降解聚合物中提供适当的配方时，这种缓解可以持续至少三天。在某些实施例中，缓解可以持续至少25天、至少50天、至少100天、至少135天或至少180天。
• COMPOSITION FOR INHIBITING AFTER-CATARACT AND METHOD FOR PREPARING SAME
  申请人：BMI Korea Co. Ltd

  公开号：EP2792356A1

  公开（公告）日：2014-10-22

  The present invention relates to a composition for inhibiting after-cataract including a hydrophilic sulfasalazine; a high content of hyaluronic acid; and a carrier containing an aqueous solution, and a method of preparing a composition for inhibiting after-cataract including the steps of adding hyaluronic acid powder to a hydrophilized sulfasalazine; and mixing the same with a specific condition.

  本发明涉及一种抑制后发性白内障的组合物，包括亲水性的磺胺嘧啶；高含量的透明质酸；以及含有水溶液的载体，还涉及一种制备抑制后发性白内障组合物的方法，包括以下步骤：在亲水性磺胺嘧啶中加入透明质酸粉末；以及将其与特定条件混合。
• High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
  申请人：Yu Chongxi

  公开号：US10233197B2

  公开（公告）日：2019-03-19

  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

  本发明提供了新型抗菌剂和抗菌剂相关化合物的高渗透组合物（HPC）或高渗透原药（HPP），它们能够以高渗透效率穿过生物屏障。HPPs 在穿过生物屏障后能够转化为母体活性药物或药物代谢物，因此能够提供母体药物或代谢物所能提供的治疗条件。此外，HPPs 还能到达母体药物可能无法到达的区域，或在目标区域产生足够的浓度，从而提供新的治疗方法。HPPs 可通过各种给药途径给药，例如，以高浓度局部给药到疾病的作用部位，或系统地给药到生物体内，以更快的速度进入血液循环。
• Drug depots for treatment of pain and inflammation
  申请人：Medtronic, Inc.

  公开号：US10653619B2

  公开（公告）日：2020-05-19

  Effective treatments of pain and/or inflammation are provided. Through the administration of a porous biodegradable drug depot film, patch, strip or sponge being implantable within a nasal or sinus cavity and having pores sized to prevent the depot from functioning as a scaffold for tissue growth, one can reduce, prevent or treat pain and/or inflammation and prevent cells from infiltrating the drug depot and laying down scaffolding cells.

  提供了有效治疗疼痛和/或炎症的方法。通过在鼻腔或鼻窦内植入多孔可生物降解药库薄膜、贴片、条状或海绵，并使其具有一定大小的孔隙以防止药库作为组织生长的支架，可以减轻、预防或治疗疼痛和/或炎症，并防止细胞渗入药库和铺设支架细胞。